Pascale Diesel recently wrote an article that explores the high cost of gene and cell therapies and the need for companies to provide higher levels of support for healthcare providers and patients through access, reimbursement, and financing.
The new generation of emerging gene and cell therapy companies are advancing many promising treatments for major areas of unmet need in healthcare and have the potential to transform the biopharmaceutical industry in the future. The sector as a whole is trending toward more M&A deals, meaning smaller life sciences companies need to consider several factors before implementing a commercialization strategy.Their success will be based on their ability to refine their go-to-market models, geographic strategies, and maximize efficiency.
100 days. 15 executive orders. Some bold healthcare policies.
In this CRA Insights, we assess the actions and impact of the second Trump Administration during the first 100 days that directly affect healthcare policy,...